Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
SynKinase
LEE011
71
CHF
CHF 71.00
In stock
SYN-1213-M0011 mgCHF 71.00
SYN-1213-M0055 mgCHF 114.00
SYN-1213-M01010 mgCHF 170.00
SYN-1213-M05050 mgCHF 497.00
SYN-1213-M100100 mgCHF 780.00
| Product Details | |
|---|---|
| Synonyms | LEE-011; Ribociclib |
| Product Type | Chemical |
| Properties | |
| Formula | C23H30N8O |
| MW | 434.5 |
| CAS | 1211441-98-3 |
| Purity Chemicals | ≥95% |
| Appearance | Solid. |
| Solubility | Soluble in DMSO. |
| Declaration | Manufactured by SynKinase. |
| Other Product Data |
Target: CDK4/CDK6 | Kinase Group: CGMC | Substrate: Serine-Threonine Click here for Original Manufacturer Product Datasheet Our product description may differ slightly from the original manufacturers product datasheet. |
| InChi Key | RHXHGRAEPCAFML-UHFFFAOYSA-N |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Use/Stability | Stable for at least 2 years after receipt when stored at -20°C. |
| Documents | |
| MSDS |
 Download PDF |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
Description
Orally available cyclin-dependent kinase (CDK) inhibitor targeting cyclin D1/CDK4 and cyclin D3/CDK6 cell cycle pathways, with potential antineoplastic activity. Specifically inhibits CDK4 and 6, thereby inhibiting retinoblastoma (Rb) protein phosphorylation. Inhibition of Rb phosphorylation prevents CDK-mediated G1-S phase transition, thereby arresting the cell cycle in the G1 phase, suppressing DNA synthesis and inhibiting cancer cell growth. Overexpression of CDK4/6, as seen in certain types of cancer, causes cell cycle deregulation.
Product References
- Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma: J. Rader, et al.; Clin. Cancer Res. 19, 6173 (2013)
- Molecular pathways: CDK4 inhibitors for cancer therapy: M.A. Dickson; Clin. Cancer Res. 20, 3379 (2014)
- Antiproliferative effects of CDK4/6 inhibition in CDK4-amplified human liposarcoma in vitro and in vivo: Y.X. Zhang, et al.; Mol. Cancer Ther. 13, 2184 (2014)
Related Products
